Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Theseus Pharmaceuticals Inc (THRX)

Theseus Pharmaceuticals Inc (THRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results PR Newswire - Thu Aug 10, 2023

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024...

THRX : 4.06 (unch)
Why These 2 Biotech Stocks Made Big Moves Late Thursday Motley Fool - Thu Jul 13, 2023

Markets kept powering higher on the day.

COMP : 6.00 (-10.45%)
$NASX : 19,392.69 (-3.56%)
$DOWI : 42,326.87 (-2.58%)
$SPX : 5,872.16 (-2.95%)
ACAD : 16.91 (-2.87%)
THRX : 4.06 (unch)
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST PR Newswire - Thu Jul 13, 2023

-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a...

THRX : 4.06 (unch)
Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference PR Newswire - Wed May 31, 2023

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

THRX : 4.06 (unch)
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST PR Newswire - Thu May 25, 2023

-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed...

THRX : 4.06 (unch)
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results PR Newswire - Thu May 11, 2023

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

THRX : 4.06 (unch)
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting PR Newswire - Wed Apr 26, 2023

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

THRX : 4.06 (unch)
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire - Tue Apr 11, 2023

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

THRX : 4.06 (unch)
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium PR Newswire - Tue Mar 28, 2023

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

THRX : 4.06 (unch)
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire - Thu Mar 9, 2023

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

THRX : 4.06 (unch)

Barchart Exclusives

2 Dividend Stocks Analysts Love for Fat Yields in 2025 Barchart - Wed Dec 18, 6:30PM CST
These companies have high yields and have strong business models that position them to maintain and potentially increase their dividend payments in 2025. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot